Up a level |
Number of items: 1.
Davies, MJ, Baldry, EL, Bodicoat, DH, Chatterjee, S, Edwardson, CL, Gray, LJ, Khunti, K, Sargeant, JA, Stensel, DJ, Webb, DR et al (show 4 more authors)
(2020)
The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes.
.